| Prev Close | 68.51 |
| Day Low/High | 67.92 / 69.17 |
| 52 Wk Low/High | 60.89 / 85.97 |
Gilead Sciences, Inc. (GILD)
68.10
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1253.72B |
| Market Cap | 85.89B |
| P/E Ratio | 17.57 |
| Div & Yield | N.A. (N.A) |
Jim Cramer: We're Not Yet Inured to Coronavirus Disappointment
Microsoft says it will miss its personal computer forecast, but Marriott appears to be trading up a tad.
Moderna Could Spike Much Higher as the Pandemic Story Plays Out
Hot money will be attracted to stocks that show promise in dealing with the coronavirus.
Jim Cramer: 3 Market Storylines Are In Play, But Which Is Best for Investors?
Only one of these scenarios is going to get you in and out of this market with your assets intact and your portfolio stronger.
Jim Cramer: Hope for the Best, Plan for the Worst
Is this the end of the world? No. You still need to plan for your financial well-being, even as the CDC tells us 'this might be bad.'
Jim Cramer: Want the Bulls' Biggest Nightmare? Here It Is
This entirely logical scenario would pull the rug out from under the bull market.
Jim Cramer: Do You Really Want to Sell Now?
The answer to that question depends on several factors, so let's break them down.
Gilead Gets Some Serious Play
I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good.
Gilead Has Become and Will Be a Volatile Name
I would consider any entry a trade, and not an investment.
Shares of Gilead Could Surge to the $88 Area in the Near-Term
Any modest intraday dip is probably a buying opportunity.
There's Now Reason, and Science, to Playing GILD
Here's what the charts say about entering Gilead Sciences.
Gilead Sciences Coronavirus Treatment News Could Lead to Key Upside Breakout
Company has an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on coronavirus patients.
This Drugmaking Dividend Stock Due for Shot in the Arm
Gilead offers a nearly 4% yield and looks ready to return to growth.
Target the Bullish Pattern in Gilead Sciences
Also, another buy setup is emerging in Nutanix.
Alibaba, Salesforce, Constellation Software Make RBC's List of Top 2020 Picks
RBC analysts expect Alibaba and Salesforce to continue posting strong double-digit sales growth, and remain fans of Constellation's M&A-driven growth strategy.
3 Biotech Stocks With the Best-Looking Charts
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
Markets Looking Good
"Politics: "Poli" a Latin word meaning "many" and "tics" meaning "bloodsucking creatures" - Robin Williams Markets are looking good a half hour into the trading day. All the major indices are nicely in the black with the NASDAQ up approximately one ...
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
3 Trends Driving This Earnings Season
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
One Prescription for Uncertain Market? Gilead Sciences
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
I'm Looking at Gilead and Merck for Buy Entry Positions
Let's see if either of these names provide an entry this week.
Buyout Speculation Picks Up in Biotech
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
3 Autopilot Funds for a High-Yield Portfolio
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
